Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jun 2013

Koers Karlijn, Francken Anne Brecht, Haanen John B A G, Woerdeman Leonie A E, van der Hage Jos A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indoles
Share to Lymph Nodes
Share to Lymphatic Metastasis
Share to Multimodal Imaging

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoadjuvant Therapy

Share to Positron-Emission Tomography

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 23569313
DOI: 10.1200/JCO.2012.45.3845

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.PMID 23569313Read ↗

FDA approves vemurafenib for treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib for leptomeningeal melanomatosis.Semantic proximity Read ↗

Melanoma: Time for adjuvant vemurafenib?Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

Community experience of vemurafenib for BRAF(V600) melanoma.Semantic proximity Read ↗

Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Semantic proximity Read ↗

Systemic Therapy Options for Patients With Unresectable Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.